Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid achieves record quarterly sales for its hair care products

First time that Cellmid has recorded quarterly sales above $2 million.
rising sales bar chart
More than double the sales from the same period last year

Cellmid Limited’s (ASX:CDY) sales of its FGF5 inhibitor hair growth and anti-aging hair care products for Q2 FY2018 reached circa $2 million, more than double the sales from the same period last year.

The company’s consumer health subsidiary Advangen sells hair care products in Australia, Japan and the U.S.

Quarterly sales exceed $2 million for the first time

This is the first time that Cellmid has recorded sales above $2 million for the quarter, having achieved a 34% increase on the highest previous quarterly result of $1.5 million.

The substantial increase in sales was the result of continued success with television shopping channel QVC in Japan.

Cellmid’s ‘million-dollar day’ sale on 21 December 2017 on the QVC television shopping channel in Japan has been a remarkable success.

The company also benefited from the commencement of shipping to China following the receipt of import permits for the Jo-Ju® and Lexilis® branded products.

READ: Cellmid makes move to sell hair loss products into China

The company had signed a master supply agreement with YPB Group Ltd (ASX:YPB) to market the company’s products in China.

This is part of a comprehensive strategy to enter the Chinese consumer health market with the company’s various brands of FGF5 inhibitor hair loss products.

READ: Cellmid ends the year on a high note after achieving quarterly targets

Cellmid has achieved key milestones and operational targets for the quarter ended 31 December 2017.

The company recently signed up with its second U.S. retail partner, Soft Surroundings.  Cellmid had successfully launched its product range on Neiman Marcus online earlier last year.

The évolis® Professional anti-aging hair care products were launched in Australian salons in November 2017. The roll-out, primarily through wholesale relationships, will continue in 2018.

Rare kidney disease studies progressing well

Cellmid’s ‘in live’ phase of the FSGS (a rare disease that attacks the kidney) studies at the Westmead Institute in Sydney was completed in December 2017.

The tissue and blood data are currently being analysed with an early indication that one of the company’s antibodies, not previously tested, is showing efficacy in this model.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
bacteria
June 27 2018
Ridinilazole is a possible treatment for C. Difficile and Summit hopes to kick off a phase III trial in the first quarter of 2019
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use